{"success":true,"data":{"pressRelease":{"id":"53623","rtpr_id":"nPnbDBn10a","ticker":"DCOY","exchange":"NASDAQ","all_tickers":["DCOY"],"title":"Decoy Therapeutics Nominates Global Biopharma Executive Patricia Gauthier for Election to Board of Directors","author":"PR Newswire","published_at":"2026-06-03T12:00:29.307Z","article_body":"Decoy Therapeutics Nominates Global Biopharma Executive Patricia Gauthier for Election to Board of Directors\n\nPR Newswire\n\nCAMBRIDGE, Mass., June 3, 2026\n\nCAMBRIDGE, Mass., June 3, 2026 /PRNewswire/ -- Decoy Therapeutics Inc.\n(Nasdaq: DCOY), a biotechnology company pioneering Designable Multi-Antivirals\n(D-MAVs™), a new category of antivirals engineered to target shared viral\nmechanisms, today announced the nomination of Patricia Gauthier, MBA, LL.B.,\nas a Class II director. Ms. Gauthier's nomination will be voted on at the\nCompany's 2026 Annual Meeting of Stockholders on July 14, 2026.\n\n(https://mma.prnewswire.com/media/2859955/Decoy_Therapeutics_Logo.html)\n\n\"Patricia has spent her career making sure important medicines reach the\npeople who need them, at scale and in the real world. As we advance our D-MAV\nprograms toward the clinic, her experience building commercial organizations,\nsecuring national health security partnerships and delivering medicines across\nborders will help us turn a new approach to antiviral disease into real-world\nimpact,\" said Rick Pierce, Chief Executive Officer of Decoy Therapeutics. \"As\nDavid Arthur completes his service on our Board, we want to thank him for his\nlongstanding contributions to Decoy's predecessor, Salarius Pharmaceuticals,\nand his more recent service on Decoy's Board. Patricia's experience makes her\nan ideal choice to build on that foundation.\"\n\nMs. Gauthier has served as Senior Vice President, Regional Head for Australia,\nCanada and the United Kingdom at Moderna since 2025, leading strategy and\noperations across biomanufacturing, national health security partnerships and\ncommercialization for a region of approximately 500 employees. She previously\nserved as General Manager of Moderna Canada, where she built the affiliate\nfrom inception, supported the delivery of more than 50 million COVID-19\nvaccine doses, and helped secure a landmark biomanufacturing partnership with\nthe Government of Canada. She also held senior leadership roles at GSK across\nvaccines, specialty care, market access and government affairs. She began her\ncareer as a lawyer at McCarthy Tétrault, practicing business law, securities\nand commercial litigation.\n\n\"One of the hardest questions in infectious disease is how to prepare for\nviral threats before they emerge. Decoy's D-MAV approach offers a different\nmodel for antivirals: adaptable medicines designed to work across related\nviruses by targeting shared viral mechanisms,\" said Ms. Gauthier. \"That could\nexpand what is possible in viral prevention and treatment. Having spent my\ncareer bringing medicines to patients across diverse markets and health\nsystems, I look forward to helping Decoy plan early for how that science can\nreach patients.\"\n\nAbout Decoy Therapeutics\n\nDecoy Therapeutics is a biotechnology company pioneering Designable\nMulti-Antivirals (D-MAVs), a new category of antivirals engineered to target\nshared viral mechanisms, enabling a single, adaptable drug to work across\nmultiple viruses. Built on the proprietary IMP³ACT™ platform, which\ncombines AI-assisted design and rapid synthesis, Decoy develops peptide\nantivirals designed to move faster into the clinic and expand what is possible\nin viral prevention and treatment. The company's lead candidates target\nmultiple respiratory viruses, addressing the health and societal burden of\nviral disease.\n\nForward Looking Statements\nThis press release contains \"forward-looking statements\" within the meaning of\nthe Private Securities Litigation Reform Act of 1995 regarding Decoy,\nincluding expected achievement of milestones for its lead asset and future\nprospects of Decoy. These statements may discuss goals, intentions and\nexpectations as to future plans, trends, events, results of operations or\nfinancial condition, or otherwise, based on current beliefs of the management\nof Decoy, as well as assumptions made by, and information currently available\nto, management. Forward-looking statements generally include statements that\nare predictive in nature and depend upon or refer to future events or\nconditions, and include words such as \"may,\" \"will,\" \"can,\" \"should,\" \"would,\"\n\"expect,\" \"anticipate,\" \"plan,\" \"likely,\" \"believe,\" \"estimate,\" \"project,\"\n\"intend,\" and other similar expressions. Statements that are not historical\nfacts are forward-looking statements. Forward-looking statements are based on\ncurrent beliefs and assumptions that are subject to risks and uncertainties\nand are not guarantees of future performance. Actual results could differ\nmaterially from those contained in any forward-looking statement as a result\nof various factors, including, without limitation: the risk that the Company\nwill not obtain sufficient financing to execute on their business plans and\nrisks related to Decoy's products and development plans, including\nunanticipated issues with any IND application process and the potential of the\nIMP(3)ACT(™) platform. Readers are urged to carefully review and consider\nthe various disclosures made by the Company in its reports filed with the SEC,\nincluding its Annual Report on Form 10-K for the fiscal year ended December\n31, 2025, as revised or supplemented by its Quarterly Reports on Form 10-Q and\nother documents filed with the SEC. If one or more of these risks or\nuncertainties materialize, or if the underlying assumptions prove incorrect,\nDecoy's actual results may vary materially from those expected or projected.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/decoy-therapeutics-nominates-global-biopharma-executive-patricia-gauthier-for-election-to-board-of-directors-302789315.html\n(https://www.prnewswire.com/news-releases/decoy-therapeutics-nominates-global-biopharma-executive-patricia-gauthier-for-election-to-board-of-directors-302789315.html)\n\nSOURCE Decoy Therapeutics, Inc\n\n\n\nContacts: Decoy Therapeutics: Rick Pierce, CEO, pierce@decoytx.com, 617-447-8299; Business Development: Peter Marschel, CBO, peter@decoytx.com, 617-943-6305; Media Relations: Tara Mulloy, tara@tmc-studio.com, (978) 855-5219\n\nPhoto: \nhttps://mma.prnewswire.com/media/2859955/Decoy_Therapeutics_Logo.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPnbDBn10a","title":"Decoy Therapeutics Nominates Global Biopharma Executive Patricia Gauthier for Election to Board of Directors","author":"PR Newswire","ticker":"DCOY","created":"2026-06-03T12:00:29.307Z","tickers":["DCOY"],"exchange":"NASDAQ","article_body":"Decoy Therapeutics Nominates Global Biopharma Executive Patricia Gauthier for Election to Board of Directors\n\nPR Newswire\n\nCAMBRIDGE, Mass., June 3, 2026\n\nCAMBRIDGE, Mass., June 3, 2026 /PRNewswire/ -- Decoy Therapeutics Inc.\n(Nasdaq: DCOY), a biotechnology company pioneering Designable Multi-Antivirals\n(D-MAVs™), a new category of antivirals engineered to target shared viral\nmechanisms, today announced the nomination of Patricia Gauthier, MBA, LL.B.,\nas a Class II director. Ms. Gauthier's nomination will be voted on at the\nCompany's 2026 Annual Meeting of Stockholders on July 14, 2026.\n\n(https://mma.prnewswire.com/media/2859955/Decoy_Therapeutics_Logo.html)\n\n\"Patricia has spent her career making sure important medicines reach the\npeople who need them, at scale and in the real world. As we advance our D-MAV\nprograms toward the clinic, her experience building commercial organizations,\nsecuring national health security partnerships and delivering medicines across\nborders will help us turn a new approach to antiviral disease into real-world\nimpact,\" said Rick Pierce, Chief Executive Officer of Decoy Therapeutics. \"As\nDavid Arthur completes his service on our Board, we want to thank him for his\nlongstanding contributions to Decoy's predecessor, Salarius Pharmaceuticals,\nand his more recent service on Decoy's Board. Patricia's experience makes her\nan ideal choice to build on that foundation.\"\n\nMs. Gauthier has served as Senior Vice President, Regional Head for Australia,\nCanada and the United Kingdom at Moderna since 2025, leading strategy and\noperations across biomanufacturing, national health security partnerships and\ncommercialization for a region of approximately 500 employees. She previously\nserved as General Manager of Moderna Canada, where she built the affiliate\nfrom inception, supported the delivery of more than 50 million COVID-19\nvaccine doses, and helped secure a landmark biomanufacturing partnership with\nthe Government of Canada. She also held senior leadership roles at GSK across\nvaccines, specialty care, market access and government affairs. She began her\ncareer as a lawyer at McCarthy Tétrault, practicing business law, securities\nand commercial litigation.\n\n\"One of the hardest questions in infectious disease is how to prepare for\nviral threats before they emerge. Decoy's D-MAV approach offers a different\nmodel for antivirals: adaptable medicines designed to work across related\nviruses by targeting shared viral mechanisms,\" said Ms. Gauthier. \"That could\nexpand what is possible in viral prevention and treatment. Having spent my\ncareer bringing medicines to patients across diverse markets and health\nsystems, I look forward to helping Decoy plan early for how that science can\nreach patients.\"\n\nAbout Decoy Therapeutics\n\nDecoy Therapeutics is a biotechnology company pioneering Designable\nMulti-Antivirals (D-MAVs), a new category of antivirals engineered to target\nshared viral mechanisms, enabling a single, adaptable drug to work across\nmultiple viruses. Built on the proprietary IMP³ACT™ platform, which\ncombines AI-assisted design and rapid synthesis, Decoy develops peptide\nantivirals designed to move faster into the clinic and expand what is possible\nin viral prevention and treatment. The company's lead candidates target\nmultiple respiratory viruses, addressing the health and societal burden of\nviral disease.\n\nForward Looking Statements\nThis press release contains \"forward-looking statements\" within the meaning of\nthe Private Securities Litigation Reform Act of 1995 regarding Decoy,\nincluding expected achievement of milestones for its lead asset and future\nprospects of Decoy. These statements may discuss goals, intentions and\nexpectations as to future plans, trends, events, results of operations or\nfinancial condition, or otherwise, based on current beliefs of the management\nof Decoy, as well as assumptions made by, and information currently available\nto, management. Forward-looking statements generally include statements that\nare predictive in nature and depend upon or refer to future events or\nconditions, and include words such as \"may,\" \"will,\" \"can,\" \"should,\" \"would,\"\n\"expect,\" \"anticipate,\" \"plan,\" \"likely,\" \"believe,\" \"estimate,\" \"project,\"\n\"intend,\" and other similar expressions. Statements that are not historical\nfacts are forward-looking statements. Forward-looking statements are based on\ncurrent beliefs and assumptions that are subject to risks and uncertainties\nand are not guarantees of future performance. Actual results could differ\nmaterially from those contained in any forward-looking statement as a result\nof various factors, including, without limitation: the risk that the Company\nwill not obtain sufficient financing to execute on their business plans and\nrisks related to Decoy's products and development plans, including\nunanticipated issues with any IND application process and the potential of the\nIMP(3)ACT(™) platform. Readers are urged to carefully review and consider\nthe various disclosures made by the Company in its reports filed with the SEC,\nincluding its Annual Report on Form 10-K for the fiscal year ended December\n31, 2025, as revised or supplemented by its Quarterly Reports on Form 10-Q and\nother documents filed with the SEC. If one or more of these risks or\nuncertainties materialize, or if the underlying assumptions prove incorrect,\nDecoy's actual results may vary materially from those expected or projected.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/decoy-therapeutics-nominates-global-biopharma-executive-patricia-gauthier-for-election-to-board-of-directors-302789315.html\n(https://www.prnewswire.com/news-releases/decoy-therapeutics-nominates-global-biopharma-executive-patricia-gauthier-for-election-to-board-of-directors-302789315.html)\n\nSOURCE Decoy Therapeutics, Inc\n\n\n\nContacts: Decoy Therapeutics: Rick Pierce, CEO, pierce@decoytx.com, 617-447-8299; Business Development: Peter Marschel, CBO, peter@decoytx.com, 617-943-6305; Media Relations: Tara Mulloy, tara@tmc-studio.com, (978) 855-5219\n\nPhoto: \nhttps://mma.prnewswire.com/media/2859955/Decoy_Therapeutics_Logo.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-06-03T12:00:29.367122517Z","server_sent_at_ms":1780488029367},"received_at":"2026-06-03T12:00:29.431Z","source_url":"https://www.prnewswire.com/news-releases/decoy-therapeutics-nominates-global-biopharma-executive-patricia-gauthier-for-election-to-board-of-directors-302789315.html"},"analysis":{"id":"43054","press_release_id":"53623","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"board_change","narrative":"Decoy Therapeutics nominated Patricia Gauthier for election as a Class II director at its upcoming annual meeting.\n\nGauthier brings extensive commercial and operational experience from Moderna, GSK, and the Canadian government, replacing outgoing director David Arthur.\n\nThe move signals a focus on commercialization and global health security partnerships as the company advances its D-MAV platform toward clinical trials.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Board refresh with commercial expertise ahead of clinical milestones."},"keyFigures":{},"quotedText":"Patricia has spent her career making sure important medicines reach the people who need them, at scale and in the real world.","namedEntities":{"people":[{"name":"Patricia Gauthier","role":"Nominee for Class II Director"},{"name":"Rick Pierce","role":"CEO"},{"name":"David Arthur","role":"Outgoing Director"},{"name":"Peter Marschel","role":"CBO"},{"name":"Tara Mulloy","role":"Media Relations"}],"products":["D-MAVs","Designable Multi-Antivirals","IMP³ACT platform"],"companies":[{"name":"Decoy Therapeutics Inc.","ticker":"DCOY","relationship":"filer"},{"name":"Moderna","relationship":"former employer of nominee"},{"name":"GSK","relationship":"former employer of nominee"},{"name":"Salarius Pharmaceuticals","relationship":"predecessor company"},{"name":"McCarthy Tétrault","relationship":"former employer of nominee"},{"name":"Government of Canada","relationship":"partner mentioned in bio"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine board nomination of a new director with relevant industry experience. No change in executive leadership or strategic direction; standard corporate governance update."},"tickerRelevance":{"others":[{"ticker":"MRNA","relevance":"former employer of new board member"}],"primary":"DCOY"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"routine_board_change","sectorWeight":"biotech","marketCapAdjustment":"low"}},"event_type":"board_change","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Decoy Therapeutics nominated Patricia Gauthier for election as a Class II director at its upcoming annual meeting.\n\nGauthier brings extensive commercial and operational experience from Moderna, GSK, and the Canadian government, replacing outgoing director David Arthur.\n\nThe move signals a focus on commercialization and global health security partnerships as the company advances its D-MAV platform toward clinical trials.","key_figures":{},"named_entities":{"people":[{"name":"Patricia Gauthier","role":"Nominee for Class II Director"},{"name":"Rick Pierce","role":"CEO"},{"name":"David Arthur","role":"Outgoing Director"},{"name":"Peter Marschel","role":"CBO"},{"name":"Tara Mulloy","role":"Media Relations"}],"products":["D-MAVs","Designable Multi-Antivirals","IMP³ACT platform"],"companies":[{"name":"Decoy Therapeutics Inc.","ticker":"DCOY","relationship":"filer"},{"name":"Moderna","relationship":"former employer of nominee"},{"name":"GSK","relationship":"former employer of nominee"},{"name":"Salarius Pharmaceuticals","relationship":"predecessor company"},{"name":"McCarthy Tétrault","relationship":"former employer of nominee"},{"name":"Government of Canada","relationship":"partner mentioned in bio"}],"dollarAmounts":[]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-04T05:58:37.300Z","global_importance":15,"audience_relevance":10,"importance_components":{"tickerTier":"small-cap","eventGravity":"routine_board_change","sectorWeight":"biotech","marketCapAdjustment":"low"}},"durationMs":34466,"modelName":"george-droid-qwen-72b"}}